238 related articles for article (PubMed ID: 38409643)
21. Targeting BRAF and MEK inhibitors in melanoma in the metastatic, neoadjuvant and adjuvant setting.
Tétu P; Baroudjian B; Lebbe C
Curr Opin Oncol; 2020 Mar; 32(2):85-90. PubMed ID: 31895121
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant immunotherapy for melanoma patients: progress and opportunities.
Sussman TA; Ott PA
ESMO Open; 2024 May; 9(5):102962. PubMed ID: 38626633
[TBL] [Abstract][Full Text] [Related]
23. New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distant Metastatic Melanoma.
Barker CA; Salama AK
J Natl Compr Canc Netw; 2018 May; 16(5S):646-650. PubMed ID: 29784747
[TBL] [Abstract][Full Text] [Related]
24. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.
Dummer R; Lebbé C; Atkinson V; Mandalà M; Nathan PD; Arance A; Richtig E; Yamazaki N; Robert C; Schadendorf D; Tawbi HA; Ascierto PA; Ribas A; Flaherty KT; Pakhle N; Campbell CD; Gusenleitner D; Masood A; Brase JC; Gasal E; Long GV
Nat Med; 2020 Oct; 26(10):1557-1563. PubMed ID: 33020648
[TBL] [Abstract][Full Text] [Related]
25. COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma.
van Akkooi AC; Hauschild A; Long GV; Mandala M; Kicinski M; Govaerts AS; Klauck I; Ouali M; Lorigan PC; Eggermont AM
Future Oncol; 2023 Sep; 19(30):2017-2027. PubMed ID: 37665297
[TBL] [Abstract][Full Text] [Related]
26. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
[TBL] [Abstract][Full Text] [Related]
27. The Role of Neoadjuvant Therapy in Melanoma.
Kelly ZR; Gorantla VC; Davar D
Curr Oncol Rep; 2020 Jun; 22(8):80. PubMed ID: 32601947
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.
Corrie PG; Marshall A; Nathan PD; Lorigan P; Gore M; Tahir S; Faust G; Kelly CG; Marples M; Danson SJ; Marshall E; Houston SJ; Board RE; Waterston AM; Nobes JP; Harries M; Kumar S; Goodman A; Dalgleish A; Martin-Clavijo A; Westwell S; Casasola R; Chao D; Maraveyas A; Patel PM; Ottensmeier CH; Farrugia D; Humphreys A; Eccles B; Young G; Barker EO; Harman C; Weiss M; Myers KA; Chhabra A; Rodwell SH; Dunn JA; Middleton MR; ; Nathan P; Lorigan P; Dziewulski P; Holikova S; Panwar U; Tahir S; Faust G; Thomas A; Corrie P; Sirohi B; Kelly C; Middleton M; Marples M; Danson S; Lester J; Marshall E; Ajaz M; Houston S; Board R; Eaton D; Waterston A; Nobes J; Loo S; Gray G; Stubbings H; Gore M; Harries M; Kumar S; Goodman A; Dalgleish A; Martin-Clavijo A; Marsden J; Westwell S; Casasola R; Chao D; Maraveyas A; Marshall E; Patel P; Ottensmeier C; Farrugia D; Humphreys A; Eccles B; Dega R; Herbert C; Price C; Brunt M; Scott-Brown M; Hamilton J; Hayward RL; Smyth J; Woodings P; Nayak N; Burrows L; Wolstenholme V; Wagstaff J; Nicolson M; Wilson A; Barlow C; Scrase C; Podd T; Gonzalez M; Stewart J; Highley M; Wolstenholme V; Grumett S; Goodman A; Talbot T; Nathan K; Coltart R; Gee B; Gore M; Farrugia D; Martin-Clavijo A; Marsden J; Price C; Farrugia D; Nathan K; Coltart R; Nathan K; Coltart R
Ann Oncol; 2018 Aug; 29(8):1843-1852. PubMed ID: 30010756
[TBL] [Abstract][Full Text] [Related]
29. Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations.
Ascierto PA; Capone M; Grimaldi AM; Mallardo D; Simeone E; Madonna G; Roder H; Meyer K; Asmellash S; Oliveira C; Roder J; Grigorieva J
J Immunother Cancer; 2019 Mar; 7(1):91. PubMed ID: 30925943
[TBL] [Abstract][Full Text] [Related]
30. Conjunctival Melanoma: Current Treatments and Future Options.
Grimes JM; Shah NV; Samie FH; Carvajal RD; Marr BP
Am J Clin Dermatol; 2020 Jun; 21(3):371-381. PubMed ID: 31965542
[TBL] [Abstract][Full Text] [Related]
31. Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with
Tawbi HA; Robert C; Brase JC; Gusenleitner D; Gasal E; Garrett J; Savchenko A; Görgün G; Flaherty KT; Ribas A; Dummer R; Schadendorf D; Long GV; Nathan PD; Ascierto PA
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35728875
[TBL] [Abstract][Full Text] [Related]
32. Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation.
Kiniwa Y; Nakamura K; Mikoshiba A; Ashida A; Akiyama Y; Morimoto A; Okuyama R
BMC Cancer; 2021 Mar; 21(1):287. PubMed ID: 33731038
[TBL] [Abstract][Full Text] [Related]
33. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
34. Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.
Samlowski W; Adajar C
BMC Cancer; 2021 Nov; 21(1):1187. PubMed ID: 34743688
[TBL] [Abstract][Full Text] [Related]
35. Which adjuvant treatment for patients with BRAF
Funck-Brentano E; Malissen N; Roger A; Lebbé C; Deilhes F; Frénard C; Dréno B; Meyer N; Grob JJ; Tétu P; Saiag P
Ann Dermatol Venereol; 2021 Sep; 148(3):145-155. PubMed ID: 33579557
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
[TBL] [Abstract][Full Text] [Related]
37. Comparative analysis of adjuvant therapy for stage III BRAF-mut melanoma: A real-world retrospective study from single center in China.
Zhong J; Sun W; Hu T; Wang C; Yan W; Luo Z; Liu X; Xu Y; Chen Y
Cancer Med; 2023 May; 12(10):11475-11482. PubMed ID: 37016119
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing.
van Akkooi ACJ; Zijlker LP; Wouters MWJM
BioDrugs; 2022 May; 36(3):373-380. PubMed ID: 35397089
[TBL] [Abstract][Full Text] [Related]
39. An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 monotherapies or BRAF/MEK inhibitors in a community-based oncology setting.
Cowey CL; Boyd M; Aguilar KM; Beeks A; Krepler C; Scherrer E
Cancer Med; 2020 Nov; 9(21):7863-7878. PubMed ID: 32871054
[TBL] [Abstract][Full Text] [Related]
40. TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy.
Eckardt J; Schroeder C; Martus P; Armeanu-Ebinger S; Kelemen O; Gschwind A; Bonzheim I; Eigentler T; Amaral T; Ossowski S; Rieß O; Flatz L; Garbe C; Forschner A
J Cancer Res Clin Oncol; 2023 Feb; 149(2):833-840. PubMed ID: 35192052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
